NCT01570790View on ClinicalTrials.gov

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Combretastatin A4 PhosphateAge-related Macular DegenerationAMDCNVChoroidal Neovascularization
Interventions
DRUG

Combretastatin A-4 phosphate

27 mg/m2 CA4P IV infusion at baseline and every week for 4 doses

DRUG

Combretastatin A-4 Phosphate

36 mg/m2 CA4P IV infusion at baseline and every week for 4 doses

DRUG

Combretastatin A-4 Phosphate

45 mg/m2 CA4P IV infusion at baseline and every week for 4 doses

Trial Locations (1)

21287

Wilmer Eye Institute, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT01570790 - Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter